Evidence map›Paper›PMID 41254268›Full record

ArticleDigestive diseases and sciences2026

Understanding the Link Between Patient Symptoms and Provider Goals for Mucosal Healing in IBD: Insights from the IBD Qorus Survey.

Angela Troia, Sarah Harvey, Angela Wu, Sara Kiparizoska, Alandra Weaver, Ridhima Oberai, Gil Y Melmed, Corey A Siegel, Siddharth Singh, Mark C Mattar

Abstract read
PubMed Publisher
In one paragraph

Article in Digestive diseases and sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Angela TroiaDepartment of Gastroenterology, MedStar Georgetown University Hospital, 3800 Reservoir Road NW, Building 2, Washington, DC, 20007, USA. Angela.Troia@medstar.net.
Sarah HarveyCrohn's & Colitis Foundation, New York, NY, USA.
Angela WuDepartment of Gastroenterology, MedStar Georgetown University Hospital, 3800 Reservoir Road NW, Building 2, Washington, DC, 20007, USA.
Sara KiparizoskaDepartment of Gastroenterology, MedStar Georgetown University Hospital, 3800 Reservoir Road NW, Building 2, Washington, DC, 20007, USA.
Alandra WeaverCrohn's & Colitis Foundation, New York, NY, USA.
Ridhima OberaiCrohn's & Colitis Foundation, New York, NY, USA.
Gil Y MelmedDivision of Gastroenterology and Hepatology, F Widjaja Inflammatory Bowel Disease Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Corey A SiegelCenter for Digestive Health, Section of Gastroenterology and Hepatology, Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA.
Siddharth SinghUniversity of California San Diego, Louisiana Jolla, CA, USA.
Mark C MattarDepartment of Gastroenterology, MedStar Georgetown University Hospital, 3800 Reservoir Road NW, Building 2, Washington, DC, 20007, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAlthough symptom severity has traditionally guided treatment decisions in inflammatory bowel disease (IBD), symptoms do not reliably reflect the degree of underlying intestinal inflammation. Mucosal healing has emerged as a critical treatment goal, owing to its strong association with improved long-term outcomes. Despite this paradigm shift, it is unclear how symptom severity influences clinicians' decisions to assess for or pursue mucosal healing in routine practice.

methodsWe analyzed 5460 matched patient and provider surveys collected from June 2021 to October 2022 through the Crohn's and Colitis Foundation's national quality improvement program, IBD Qorus. Patient-reported symptoms, including stool frequency, rectal bleeding, abdominal pain and general sense of wellbeing, were evaluated in relation to provider-reported plans for endoscopy, fecal calprotectin testing, and treatment changes.

resultsAmong patients reporting clinical remission, providers still planned endoscopy or stool biomarker testing within one year in over 60% of cases. Increased symptom severity-especially greater stool frequency, rectal bleeding, and worse general wellbeing-was significantly associated with earlier testing and treatment changes. Abdominal pain was not associated with these decisions. Providers expressed uncertainty regarding the timing of stool biomarker testing, particularly in patients with Crohn's disease. Higher composite symptom scores were consistently associated with an increased likelihood of both testing and treatment adjustment.

conclusionProvider decisions to assess or treat for mucosal healing are associated with, but not fully driven by, symptom severity.

Indexed as

Crohn DiseaseInflammatory Bowel DiseasesIntestinal MucosaWound HealingAdultBiomarkersFecesFemaleHumansLeukocyte L1 Antigen ComplexMaleMiddle AgedSeverity of Illness IndexSurveys and QuestionnairesBiomarkersLeukocyte L1 Antigen ComplexInflammatory bowel diseaseMucosal healingPatient-reported outcomesTreat-to-target

Identifiers

PMID41254268

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.